Discovery of Sapropterin as BH4
Sapropterin, also known as Kuvan or tetrahdyrobiopterin (BH4), was identified as the active 6R-isomer of tetrahydrobiopterin, the essential cofactor for phenylalanine hydroxylase (PAH). PAH converts phenylalanine to tyrosine, preventing phenylketonuria (PKU) buildup. Its role emerged from research in the 1970s-1980s linking cofactor deficiencies to hyperphenylalaninemia.
Initial Clues from Rare Genetic Disorders
In the mid-1970s, studies of atypical PKU patients with normal PAH but high phenylalanine levels pointed to defects in biopterin synthesis or recycling. These patients had low levels of biopterin in cerebrospinal fluid, unlike classic PKU. Researchers like Niederwieser and Curtius isolated neopterin and biopterin from patient urine, identifying pterin pathway disruptions.[1][2]
Biochemical Pathway Mapping
By 1978, Kahler and colleagues used loading tests: patients received synthetic BH4, and phenylalanine levels dropped rapidly, confirming BH4 directly activated PAH. In vitro assays showed BH4 regenerated the enzyme's iron center post-reaction, distinguishing it from ineffective oxidized forms like biopterin or sepiapterin.[3] The 6R configuration was pinpointed as active via stereochemical separation in 1981.
Key Experiments Confirming the Mechanism
- Cofactor Loading Tests: Oral or IV BH4 normalized phenylalanine in BH4-deficient patients within hours, unlike in classic PKU.[4]
- Enzyme Kinetics: PAH required BH4 for hydroxylation; without it, phenylalanine accumulated. NADH-dependent quinoid-dihydrobiopterin reductase recycled BH4.[5]
- Animal Models: Rat liver extracts confirmed BH4's role in tyrosine and neurotransmitter synthesis (via tyrosine hydroxylase and tryptophan hydroxylase).
This work earned Seymour Kaufman the 1989 Wolf Prize for elucidating BH4's multi-enzyme cofactor role.[6]
Path to Therapeutic Use
BioMarin isolated pharmaceutical-grade sapropterin (synthetic 6R-BH4) in the 1990s. FDA approval for PKU in 2007 relied on trials showing 20-30% phenylalanine reduction in responsive patients, validated by these mechanistic insights.[7]
[1] Niederwieser et al., Clin Chim Acta (1976)
[2] Curtius et al., J Inherit Metab Dis (1979)
[3] Kaufman, Adv Enzymol (1971, updated 1980s)
[4] Bartholomé et al., Pediatr Res (1978)
[5] Dhondt et al., J Pediatr (1981)
[6] Wolf Foundation Prize records
[7] FDA approval summary for Kuvan (2007)